Efficacy and safety of generic amphotericin B in experimental pulmonary aspergillosis

Vidmantas Petraitis, Ruta Petraitiene, Pengxin Lin, Karim Calis, Amy M. Kelaher, Heidi A. Muray, Christine Mya-San, Diana Mickiene, John Bacher, Thomas J. Walsh

Research output: Contribution to journalArticlepeer-review

Abstract

The recent shortage of the brand name drug Fungizone has necessitated a change to generic formulations of amphotericin B deoxycholate. Clinical trials cannot be conducted in a timely manner to provide data on the safety and efficacy of these formulations. We therefore compared generic amphotericin B and Fungizone for activity and safety in the treatment of experimental invasive pulmonary aspergillosis (IPA) in persistently neutropenic rabbits. Fungizone and generic amphotericin B are similar in efficacy, pharmacokinetics, and safety in the treatment of experimental IPA.

Original languageEnglish (US)
Pages (from-to)1642-1645
Number of pages4
JournalAntimicrobial agents and chemotherapy
Volume49
Issue number4
DOIs
StatePublished - Apr 2005

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Efficacy and safety of generic amphotericin B in experimental pulmonary aspergillosis'. Together they form a unique fingerprint.

Cite this